ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Sponsor

Genentech, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT01691898

Collaborator

(none)

231

Enrollment

Locations

Arms

76.4

Actual Duration (Months)

5.6

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination with obinutuzumab in participants with relapsed or refractory (r/r) follicular lymphoma (FL) and r/r diffuse large B-cell lymphoma (DLBCL).

Condition or Disease	Intervention/Treatment	Phase
Follicular Lymphoma Diffuse Large B-Cell Lymphoma	Drug: Obinutuzumab Drug: Pinatuzumab Vedotin Drug: Polatuzumab Vedotin Drug: Rituximab	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

231 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Actual Study Start Date :

Sep 27, 2012

Actual Primary Completion Date :

Mar 8, 2017

Actual Study Completion Date :

Feb 7, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).	Drug: Pinatuzumab Vedotin Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDT2980S Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A Drug: Rituximab RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle. Other Names: MabThera/Rituxan
Experimental: Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).	Drug: Pinatuzumab Vedotin Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDT2980S Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A Drug: Rituximab RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle. Other Names: MabThera/Rituxan
Experimental: Cohort C (FL): RTX + Polatuzumab For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.	Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A Drug: Rituximab RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle. Other Names: MabThera/Rituxan
Experimental: Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.	Drug: Obinutuzumab Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles. Other Names: GA101, Gazyva, Gazyvaro Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A
Experimental: Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.	Drug: Obinutuzumab Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles. Other Names: GA101, Gazyva, Gazyvaro Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A
Experimental: Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.	Drug: Obinutuzumab Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles. Other Names: GA101, Gazyva, Gazyvaro Drug: Polatuzumab Vedotin Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle. Other Names: DCDS4501A

Outcome Measures

Primary Outcome Measures

Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) [Baseline up to 12 months after the last dose of study treatment (up to approximately 3.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments greater than or equal to (>/=) 4 weeks after initial documentation. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as >/=50 percent (%) decrease in sum of the products of greatest diameters (SPD) of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. Participants with insufficient data to determine response were classified as non-responders.
Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) [First occurrence of objective response up to PD/relapse or death due to any cause, whichever occurred first (up to approximately 3.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014). DOR was defined as the time from the initial documentation of a CR or PR to the time of PD or death. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as >/=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to [</=] mediastinum), or 3 (uptake less than [<] mediastinum but </=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. 90% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.

Secondary Outcome Measures

Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin [Baseline, post-baseline (up to approximately 5.5 years)]
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against pinatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Number of Participants With ADA to Polatuzumab Vedotin [Baseline, post-baseline (up to approximately 5.5 years)]
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against polatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Number of Participants With ADA to Obinutuzumab [Baseline, post-baseline (up to approximately 5.5 years)]
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against obinutuzumab at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C) [Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) [Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C) [Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)]
Percentage of participants who died due to any cause was reported.
Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C) [Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)]
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by the investigator according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately greater than [>] liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately >liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. CR was defined as reduction of longest transverse diameter (LDi) of target nodes/nodal masses to less than or equal to (</=) 1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as >/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least >50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)]
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as >/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least >50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) [Baseline up to disease progression or death, whichever occurred first (up to approximately 5.5 years)]
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT or CT scan. Best OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately >liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) [Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)]
AUCinf for rituximab was estimated from serum concentration data using non-compartmental analysis.
Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) [Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)]
Cmax for rituximab was estimated from serum concentration data using non-compartmental analysis.
Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) [Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)]
CL for rituximab was estimated from serum concentration data using non-compartmental analysis.
Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) [Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)]
t1/2 for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, & 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days).
Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) [Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)]
Vss for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, & 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days)
AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with Monomethyl Auristatin E (MMAE)-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. Antibody conjugated MMAE is the total concentration of MMAE that was conjugated to the antibody.
Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUClast of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)]
Cmax of obinutuzumab was estimated from serum concentration data using non-compartmental analysis.
Overall Survival (OS): Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) [Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)]
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Percentage of Participants Who Died Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) [Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)]
Percentage of participants who died due to any cause was reported.
Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) [Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) [Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 5.5 years)]
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
Life expectancy of at least 12 weeks
History of histologically documented r/r Grades 1 to 3a FL, or r/r DLBCL
Availability of an archival or freshly biopsied tumor tissue sample must be confirmed for study enrollment
Have a clinical indication for treatment as determined by the investigator
Must have at least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or Magnetic Resonance Imaging [MRI])

Exclusion Criteria:

Prior use of any monoclonal antibody, radio-immuno-conjugate or antibody drug conjugate within 4 weeks before study start
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational anti-cancer agent within 2 weeks prior study start
Adverse events except for sensory neuropathy from any previous treatments must be resolved or stabilized to Grade less than equal to (</=) 2 prior study start
Completion of autologous stem cell transplant (SCT) within 100 days prior study start
Prior allogeneic SCT
Eligibility for autologous SCT (participants with r/r DLBCL)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of other malignancy that could affect compliance with the protocol or interpretation of results
Current or past history of central nervous system lymphoma
Current Grade >1 peripheral neuropathy
Vaccination with a live vaccine within 28 days prior to treatment

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cedars-Sinai Medical Center	Los Angeles	California	United States	90048
2	Stanford Cancer Center	Stanford	California	United States	94305-5820
3	Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center	Denver	Colorado	United States	80218
4	Georgetown University Medical Center Lombardi Cancer Center	Washington	District of Columbia	United States	20007
5	Florida Cancer Specialists - Fort Myers (Colonial Center Dr)	Fort Myers	Florida	United States	33905
6	Florida Cancer Specialists; Sarasota	Sarasota	Florida	United States	34232
7	Univ of Michigan Med School; Hematology Oncology	Ann Arbor	Michigan	United States	48109
8	Comprehensive Cancer Centers of Nevada - Eastern Avenue	Las Vegas	Nevada	United States	89169
9	Hematology Oncology Associates; Carol G. Simon Ctr	Morristown	New Jersey	United States	07960
10	Regional Cancer Care Associates LLC - Morristown	Morristown	New Jersey	United States	07962
11	Roswell Park Cancer Inst.	Buffalo	New York	United States	14263
12	New York University Cancer Cen	New York	New York	United States	10016
13	Oncology Hematology Care Inc	Cincinnati	Ohio	United States	45242
14	Willamette Valley Cancer Ctr - 520 Country Club	Eugene	Oregon	United States	97401-8122
15	Oregon Health Sciences Uni	Portland	Oregon	United States	97239
16	Sarah Cannon Cancer Center - Tennessee Oncology, Pllc	Nashville	Tennessee	United States	37203
17	Texas Oncology-Baylor Sammons Cancer Center	Dallas	Texas	United States	75246
18	Cancer Care Centers of South Texas	San Antonio	Texas	United States	78217
19	Texas Transplant Inst.	San Antonio	Texas	United States	78229
20	Texas Oncology, P.A. - Tyler; Tyler Cancer Center	Tyler	Texas	United States	75702
21	Fairfax N Virginia Hem/Onc PC	Fairfax	Virginia	United States	22031
22	Oncology & Hematolgy Associates of SW Va Inc. - Roanoke	Roanoke	Virginia	United States	24014
23	Fred Hutchinson Cancer Research Center	Seattle	Washington	United States	98109
24	Northwest Cancer Specialists - Vancouver	Vancouver	Washington	United States	98684
25	Yakima Valley Memorial Hospital/North Star Lodge	Yakima	Washington	United States	98902
26	Univ of Wisconsin-Madison	Madison	Wisconsin	United States	53705
27	Cross Cancer Institute	Edmonton	Alberta	Canada	T6G 1Z2
28	British Columbia Cancer Agency	Vancouver	British Columbia	Canada	V5Z 1H6
29	McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology	Montreal	Quebec	Canada	H3T 1E2
30	Hopital Claude Huriez - CHU Lille	Lille		France	59037
31	CHU Montpellier - Saint ELOI	Montpellier		France	34295
32	Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)	Paris		France	75475
33	Centre Hospitalier Lyon Sud	Pierre Benite		France	69495
34	Centre Henri Becquerel; Hematologie	Rouen		France	76038
35	Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V	Heidelberg		Germany	69120
36	Universitätsmedizin Johannes Gutenberg Universität; Klinik u. Poliklinik f. Neurologie	Mainz		Germany	55131
37	Klinikum d.Universität München Campus Großhadern	München		Germany	81377
38	A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna	Bologna	Emilia-Romagna	Italy	40138
39	Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2	Milano	Lombardia	Italy	20133
40	Azienda Ospedale San Giovanni	Torino	Piemonte	Italy	10126
41	Academisch Medisch Centrum; Hematologie	Amsterdam		Netherlands	1105 AZ

Sponsors and Collaborators

Genentech, Inc.

Investigators

Study Director: Clinical Trials, Genentech, Inc.

Study Documents (Full-Text)

Study Protocol and Statistical Analysis Plan - Oct 3, 2017

More Information

Publications

None provided.

Responsible Party:

Genentech, Inc.

ClinicalTrials.gov Identifier:

NCT01691898

Other Study ID Numbers:

GO27834
2011-004377-84

First Posted:

Sep 25, 2012

Last Update Posted:

Feb 21, 2020

Last Verified:

Feb 1, 2020

Additional relevant MeSH terms:

Lymphoma

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Rituximab

Obinutuzumab

Study Results

Participant Flow

Recruitment Details	A total of 289 participants were screened, out of which, 231 participants were enrolled into the study.
Pre-assignment Detail

Arm/Group Title	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with relapsed or refractory (r/r) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) received rituximab (RTX) at a dose of 375 milligrams per square meter (mg/m^2) administered via intravenous (IV) infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 milligrams per kilogram (mg/kg) administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed disease progression (PD) were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL and DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Period Title: Overall Study
STARTED	63	59	20	9	40	40
COMPLETED	16	15	11	4	26	5
NOT COMPLETED	47	44	9	5	14	35

Baseline Characteristics

Arm/Group Title	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab	Total
Arm/Group Description	Participants with relapsed or refractory [r/r] FL and DLBCL received rituximab (RTX) at a dose of 375 milligrams per square meter (mg/m^2) administered via intravenous (IV) infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 milligrams per kilogram (mg/kg) administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed disease progression (PD) were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL and DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Total of all reporting groups
Overall Participants	63	59	20	9	40	40	231
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Between 18 and 65 years	29 46%	25 42.4%	12 60%	4 44.4%	23 57.5%	16 40%	109 47.2%
>=65 years	34 54%	34 57.6%	8 40%	5 55.6%	17 42.5%	24 60%	122 52.8%
Sex: Female, Male (Count of Participants)
Female	27 42.9%	24 40.7%	8 40%	2 22.2%	16 40%	18 45%	95 41.1%
Male	36 57.1%	35 59.3%	12 60%	7 77.8%	24 60%	22 55%	136 58.9%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	2 3.2%	5 8.5%	1 5%	0 0%	0 0%	2 5%	10 4.3%
Not Hispanic or Latino	48 76.2%	44 74.6%	19 95%	9 100%	33 82.5%	36 90%	189 81.8%
Unknown or Not Reported	13 20.6%	10 16.9%	0 0%	0 0%	7 17.5%	2 5%	32 13.9%

Outcome Measures

1. Primary Outcome

Title	Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments greater than or equal to (>/=) 4 weeks after initial documentation. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as >/=50 percent (%) decrease in sum of the products of greatest diameters (SPD) of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. Participants with insufficient data to determine response were classified as non-responders.
Time Frame	Baseline up to 12 months after the last dose of study treatment (up to approximately 3.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population, which included all participants with baseline measurable disease and at least one post-baseline tumor assessment after study treatment.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	42	21	39	20	20
Number (90% Confidence Interval) [percentage of participants]	59.5 94.4%	61.9 104.9%	53.8 269%	70.0 777.8%	75.0 187.5%

2. Primary Outcome

Title	Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014). DOR was defined as the time from the initial documentation of a CR or PR to the time of PD or death. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as >/=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a >/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time Frame	First occurrence of objective response up to PD/relapse or death due to any cause, whichever occurred first (up to approximately 3.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population participants who achieved objective response.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	25	13	21	14	15
Median (Full Range) [months]	6.24	6.47	13.37	9.36	12.85

3. Primary Outcome

Title	Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H
Description	Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to [</=] mediastinum), or 3 (uptake less than [<] mediastinum but </=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. 90% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E, G, and H): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E (DLBCL): Obinutuzumab + Polatuzumab	Cohort E (FL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	4	2	34	27
Number (90% Confidence Interval) [percentage of participants]	0 0%	50.0 84.7%	35.3 176.5%	0 0%

4. Secondary Outcome

Title	Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin
Description	Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against pinatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time Frame	Baseline, post-baseline (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Analysis was performed on safety-evaluable population (only participants who received pinatuzumab vedotin). Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure and 'Number Analyzed' signifies the number of participants evaluable at specified time points.

Arm/Group Title	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	60	1
Baseline	2 3.2%
Post-baseline	0 0%	0 0%

5. Secondary Outcome

Title	Number of Participants With ADA to Polatuzumab Vedotin
Description	Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against polatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time Frame	Baseline, post-baseline (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Analysis was performed on safety-evaluable population (only participants who received polatuzumab vedotin). Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure and 'Number Analyzed' signifies the number of participants evaluable at specified time points.

Arm/Group Title	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL and DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	2	59	20	8	37	36
Baseline	1 1.6%	0 0%	0 0%	0 0%	0 0%
Post-baseline	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

6. Secondary Outcome

Title	Number of Participants With ADA to Obinutuzumab
Description	Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against obinutuzumab at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time Frame	Baseline, post-baseline (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Analysis was performed on safety-evaluable population (only participants who received obinutuzumab). Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure and 'Number Analyzed' signifies the number of participants evaluable at specified time points.

Arm/Group Title	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r FL and DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	9	37	39
Baseline	1 1.6%	2 3.4%	0 0%
Post-baseline	0 0%	0 0%	0 0%

7. Secondary Outcome

Title	Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time Frame	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	42	21	39	20	20
Number [percentage of participants]	85.7 136%	52.4 88.8%	76.9 384.5%	55.0 611.1%	60.0 150%

8. Secondary Outcome

Title	Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time Frame	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	42	21	39	20	20
Median (95% Confidence Interval) [months]	5.388	12.682	5.552	15.277	18.103

9. Secondary Outcome

Title	Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Percentage of participants who died due to any cause was reported.
Time Frame	Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	42	21	39	20	20
Number [percentage of participants]	66.7 105.9%	23.8 40.3%	61.5 307.5%	15.0 166.7%	20.0 50%

10. Secondary Outcome

Title	Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time Frame	Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	42	21	39	20	20
Median (95% Confidence Interval) [months]	16.493	NA	18.760	NA	NA

11. Secondary Outcome

Title	Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Description	Tumor response assessment was performed by the investigator according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E, G, and H): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E (DLBCL): Obinutuzumab + Polatuzumab	Cohort E (FL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	4	3	36	33
Number (90% Confidence Interval) [percentage of participants]	25.0 39.7%	66.7 113.1%	33.3 166.5%	15.2 168.9%

12. Secondary Outcome

Title	Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Description	Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately greater than [>] liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E, G, and H): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E (DLBCL): Obinutuzumab + Polatuzumab	Cohort E (FL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	4	2	34	27
Number (90% Confidence Interval) [percentage of participants]	25.0 39.7%	100.0 169.5%	64.7 323.5%	18.5 205.6%

13. Secondary Outcome

Title	Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Description	Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately >liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E, G, and H): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E (DLBCL): Obinutuzumab + Polatuzumab	Cohort E (FL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	4	3	36	33
Number (90% Confidence Interval) [percentage of participants]	25.0 39.7%	66.7 113.1%	63.9 319.5%	21.2 235.6%

14. Secondary Outcome

Title	Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. CR was defined as reduction of longest transverse diameter (LDi) of target nodes/nodal masses to less than or equal to (</=) 1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	31	36
Number (90% Confidence Interval) [percentage of participants]	6.5 10.3%	13.9 23.6%

15. Secondary Outcome

Title	Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	37	39
Number (90% Confidence Interval) [percentage of participants]	10.8 17.1%	20.5 34.7%

16. Secondary Outcome

Title	Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as >/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least >50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	31	36
Number (90% Confidence Interval) [percentage of participants]	25.8 41%	66.7 113.1%

17. Secondary Outcome

Title	Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to </=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as >/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least >50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	37	39
Number (90% Confidence Interval) [percentage of participants]	21.6 34.3%	64.1 108.6%

18. Secondary Outcome

Title	Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Description	Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT or CT scan. Best OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake </=mediastinum), or 3 (uptake <mediastinum but </=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately >liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time Frame	Baseline up to disease progression or death, whichever occurred first (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E, G, and H): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E (DLBCL): Obinutuzumab + Polatuzumab	Cohort E (FL): Obinutuzumab + Polatuzumab	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	5	4	39	39
Number (90% Confidence Interval) [percentage of participants]	20.0 31.7%	50.0 84.7%	74.4 372%	43.6 484.4%

19. Secondary Outcome

Title	Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	AUCinf for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time Frame	Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on all participants with measurable pharmacokinetic (PK) concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	25	15	26	11	15
Mean (Standard Deviation) [day*micrograms (mcg)/milliliter (mL)]	5640 (8320)	3350 (1180)	4200 (2620)	3910 (2480)	2660 (879)

20. Secondary Outcome

Title	Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Cmax for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time Frame	Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on all participants with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	36	18	35	16	18
Mean (Standard Deviation) [mcg/mL]	217 (61.5)	225 (40.9)	232 (72.7)	228 (83.3)	227 (32.4)

21. Secondary Outcome

Title	Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	CL for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time Frame	Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on all participants with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	25	15	26	11	15
Mean (Standard Deviation) [mL/day/meter-square (m^2)]	113.97 (61.41)	124.53 (41.12)	116.26 (59.99)	134.31 (97.45)	158.57 (60.47)

22. Secondary Outcome

Title	Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	t1/2 for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, & 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days).
Time Frame	Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on all participants with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	25	15	26	11	15
Mean (Standard Deviation) [days]	35.3 (56.3)	18.7 (6.23)	25.6 (18.0)	19.8 (7.34)	14.4 (3.62)

23. Secondary Outcome

Title	Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Description	Vss for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, & 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days)
Time Frame	Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)

Outcome Measure Data

Analysis Population Description
Rituximab Containing Regimens (Arms A and B, Cohort C): Analysis was performed on all participants with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	25	15	26	11	15
Mean (Standard Deviation) [mL/m^2]	2901.85 (1009.31)	2802.96 (678.33)	2988.90 (788.89)	2839.26 (730.10)	2654.46 (413.19)

24. Secondary Outcome

Title	AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUCinf of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with Monomethyl Auristatin E (MMAE)-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	27	15
Mean (Standard Deviation) [day*mcg/mL]	309 (67.7)	315 (111)

25. Secondary Outcome

Title	AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUCinf of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. Antibody conjugated MMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	17
Mean (Standard Deviation) [day*nanogram (ng)/mL]	2840 (555)	3110 (828)

26. Secondary Outcome

Title	Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUClast of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	21
Mean (Standard Deviation) [day*ng/mL]	34.2 (24.0)	33.5 (17.5)

27. Secondary Outcome

Title	Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	20
Mean (Standard Deviation) [mcg/mL]	42.5 (11.6)	48.3 (9.34)

28. Secondary Outcome

Title	Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	38	21
Mean (Standard Deviation) [ng/mL]	850 (222)	994 (190)

29. Secondary Outcome

Title	Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received pinatuzumab vedotin (Arm A) with measurable PK concentrations.

Arm/Group Title	Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	21
Mean (Standard Deviation) [ng/mL]	4.39 (3.15)	4.20 (2.32)

30. Secondary Outcome

Title	AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	26	17
Mean (Standard Deviation) [day*mcg/mL]	412 (108)	428 (106)

31. Secondary Outcome

Title	AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	30	17
Mean (Standard Deviation) [day*ng/mL]	3660 (843)	3510 (1160)

32. Secondary Outcome

Title	AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	18
Mean (Standard Deviation) [day*ng/mL]	31.7 (17.2)	29.5 (25.0)

33. Secondary Outcome

Title	Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	38	16
Mean (Standard Deviation) [mcg/mL]	51.9 (12.3)	55.9 (12.8)

34. Secondary Outcome

Title	Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	38	17
Mean (Standard Deviation) [ng/mL]	948 (204)	968 (268)

35. Secondary Outcome

Title	Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Description	Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 2.4 mg/kg in combination with rituximab (Arm B) with measurable PK concentrations.

Arm/Group Title	Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab
Arm/Group Description	Participants with r/r DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).
Measure Participants	39	18
Mean (Standard Deviation) [ng/mL]	3.72 (1.98)	3.29 (2.71)

36. Secondary Outcome

Title	AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	17
Mean (Standard Deviation) [day*mcg/mL]	258 (84.1)

37. Secondary Outcome

Title	AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	15
Mean (Standard Deviation) [day*ng/mL]	2600 (630)

38. Secondary Outcome

Title	AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	20
Mean (Standard Deviation) [day*ng/mL]	17.7 (9.39)

39. Secondary Outcome

Title	Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	19
Mean (Standard Deviation) [mcg/mL]	42.2 (7.92)

40. Secondary Outcome

Title	Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	17
Mean (Standard Deviation) [ng/mL]	787 (113)

41. Secondary Outcome

Title	Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Description	Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with rituximab (Cohort C) with measurable PK concentrations.

Arm/Group Title	Cohort C (FL): RTX + Polatuzumab
Arm/Group Description	Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	20
Mean (Standard Deviation) [ng/mL]	2.02 (1.34)

42. Secondary Outcome

Title	AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	27	30
Mean (Standard Deviation) [day*mcg/mL]	218 (89.1)	215 (102)

43. Secondary Outcome

Title	AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	26	29
Mean (Standard Deviation) [day*ng/mL]	2440 (665)	2340 (875)

44. Secondary Outcome

Title	AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	40	41
Mean (Standard Deviation) [day*ng/mL]	27.9 (21.3)	22.3 (9.46)

45. Secondary Outcome

Title	Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	37	38
Mean (Standard Deviation) [mcg/mL]	35.0 (9.89)	34.2 (7.89)

46. Secondary Outcome

Title	Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	33	33
Mean (Standard Deviation) [ng/mL]	711 (155)	694 (161)

47. Secondary Outcome

Title	Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Description	Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received polatuzumab vedotin at dose level 1.8 mg/kg in combination with obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	40	41
Mean (Standard Deviation) [ng/mL]	3.62 (3.73)	2.80 (1.30)

48. Secondary Outcome

Title	Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	Cmax of obinutuzumab was estimated from serum concentration data using non-compartmental analysis.
Time Frame	Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)

Outcome Measure Data

Analysis Population Description
Analysis was performed on all participants who received obinutuzumab (Cohort E+H and E+G) with measurable PK concentrations. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	40	35
Mean (Standard Deviation) [mcg/mL]	340 (95.0)	330 (87.9)

49. Secondary Outcome

Title	Overall Survival (OS): Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Description	OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time Frame	Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population. Here, 'Overall Number of Participants Analyzed' signifies the number of participants evaluable for this outcome measure.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	35	9
Median (95% Confidence Interval) [Months]	10.5	NA

50. Secondary Outcome

Title	Percentage of Participants Who Died Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Description	Percentage of participants who died due to any cause was reported.
Time Frame	Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	45	44
Number [percentage of participants]	77.8 123.5%	20.5 34.7%

51. Secondary Outcome

Title	Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time Frame	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	45	44
Median (95% Confidence Interval) [months]	2.7	19.5

52. Secondary Outcome

Title	Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Description	Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments >/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time Frame	Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 5.5 years)

Outcome Measure Data

Analysis Population Description
Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G): Analysis was performed on efficacy-evaluable population.

Arm/Group Title	Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab	Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.	Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
Measure Participants	45	44
Number [percentage of participants]	88.9 141.1%	56.8 96.3%

Adverse Events

	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab		Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab		Cohort C (FL): RTX + Polatuzumab		Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab		Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab		Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Time Frame	Baseline up to 30 days after the last dose of study treatment (up to approximately 12 months for rituximab-containing regimens [Arms A and B, Cohort C] and 24 weeks for Cohorts E, G, and H)
Adverse Event Reporting Description	Analysis was performed on safety-evaluable population.

Arm/Group Title	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab		Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab		Cohort C (FL): RTX + Polatuzumab		Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab		Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab		Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
Arm/Group Description	Participants with relapsed or refractory [r/r] FL and DLBCL received rituximab (RTX) at a dose of 375 milligrams per square meter (mg/m^2) administered via intravenous (IV) infusion on Day 1 and pinatuzumab vedotin at a dose of 2.4 milligrams per kilogram (mg/kg) administered via IV infusion on Day 2 for the first 2 cycles. RTX and pinatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed disease progression (PD) were treated with RTX at 375 mg/m^2 and polatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).		Participants with r/r FL and DLBCL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 2.4 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle, in the absence of any infusion-related adverse events. Participants who developed PD were treated with RTX at 375 mg/m^2 and pinatuzumab vedotin at 2.4 mg/kg via IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (maximum 17 cycles on an every-21-day schedule).		Participants with r/r FL received RTX at a dose of 375 mg/m^2 administered via IV infusion on Day 1 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first 2 cycles. In the absence of any infusion-related adverse events, RTX and polatuzumab were administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, disease progression, or withdrawal from study.		Participants with r/r FL and DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.		Participants with r/r FL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.		Participants with r/r DLBCL received obinutuzumab at a dose of 1000 mg via IV infusion on Days 1, 8, 15 and polatuzumab vedotin at a dose of 1.8 mg/kg administered via IV infusion on Day 2 for the first cycle. In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin were administered on the same day (Day 1) in subsequent cycles beginning with the second cycle for up to a maximum of 8 cycles or significant toxicity, disease progression, or withdrawal from study.
All Cause Mortality
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	35/63 (55.6%)		33/59 (55.9%)		6/20 (30%)		4/9 (44.4%)		8/40 (20%)		32/40 (80%)
Serious Adverse Events
	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab		Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab		Cohort C (FL): RTX + Polatuzumab		Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab		Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab		Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	27/63 (42.9%)		21/59 (35.6%)		8/20 (40%)		3/9 (33.3%)		9/40 (22.5%)		18/40 (45%)
Blood and lymphatic system disorders
Coagulopathy	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Febrile neutropenia	2/63 (3.2%)		2/59 (3.4%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Thrombocytopenia	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Cardiac disorders
Atrial fibrillation	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Atrial flutter	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Cardiac failure	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Cardiac failure congestive	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pericardial effusion	0/63 (0%)		0/59 (0%)		1/20 (5%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Gastrointestinal disorders
Abdominal pain	1/63 (1.6%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Abdominal pain lower	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Colonic fistula	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Constipation	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Diarrhoea	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Duodenal perforation	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Dysphagia	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Fistula of small intestine	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Gastric perforation	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Gastrointestinal haemorrhage	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Hernial eventration	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nausea	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Pancreatitis	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rectal haemorrhage	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Subileus	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Upper gastrointestinal haemorrhage	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Vomiting	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
General disorders
Axillary pain	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Chest discomfort	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Chest pain	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Fatigue	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
General physical health deterioration	2/63 (3.2%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Malaise	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Non-cardiac chest pain	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pyrexia	2/63 (3.2%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Sudden death	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hepatobiliary disorders
Bile duct obstruction	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Cholangitis	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Cholecystitis acute	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hepatic steatosis	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hepatocellular injury	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hepatomegaly	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hyperbilirubinaemia	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Liver Disorder	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Infections and infestations
Bronchitis	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Cellulitis	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Clostridial sepsis	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Clostridium difficile infection	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Device related infection	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Febrile infection	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Gastroenteritis	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Herpes zoster	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Influenza	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Lung infection	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pneumonia	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		2/40 (5%)
Sepsis	3/63 (4.8%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Septic shock	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Sinusitis	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Upper respiratory tract infection	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Urinary tract infection	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Urosepsis	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Viral diarrhoea	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Injury, poisoning and procedural complications
Infusion related reaction	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Subdural Haematoma	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Wound secretion	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Metabolism and nutrition disorders
Cachexia	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Dehydration	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hyperglycaemia	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Tumour lysis syndrome	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Musculoskeletal and connective tissue disorders
Bone pain	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ganglioneuroma	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Myelodysplastic syndrome	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nervous system disorders
Cerebrovascular accident	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Peripheral motor neuropathy	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Syncope	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hepatic Encephalopathy	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Renal and urinary disorders
Acute kidney injury	2/63 (3.2%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Chronic kidney disease	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Urinary retention	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea	1/63 (1.6%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Lung disorder	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pleural effusion	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		2/40 (5%)
Pulmonary congestion	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pulmonary embolism	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Respiratory failure	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Bronchiectasis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Vascular disorders
Hypotension	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Orthostatic hypotension	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Other (Not Including Serious) Adverse Events
	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab		Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab		Cohort C (FL): RTX + Polatuzumab		Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab		Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab		Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	63/63 (100%)		58/59 (98.3%)		20/20 (100%)		9/9 (100%)		37/40 (92.5%)		38/40 (95%)
Blood and lymphatic system disorders
Anaemia	9/63 (14.3%)		10/59 (16.9%)		1/20 (5%)		2/9 (22.2%)		4/40 (10%)		4/40 (10%)
Lymphadenopathy	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Neutropenia	19/63 (30.2%)		15/59 (25.4%)		8/20 (40%)		4/9 (44.4%)		8/40 (20%)		8/40 (20%)
Thrombocytopenia	3/63 (4.8%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		4/40 (10%)		4/40 (10%)
Cardiac disorders
Atrial fibrillation	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		1/40 (2.5%)		2/40 (5%)
Cardiac tamponade	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pericardial effusion	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Tachycardia	3/63 (4.8%)		3/59 (5.1%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Ear and labyrinth disorders
Ear discomfort	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Ear pain	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Vertigo	2/63 (3.2%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Eye disorders
Dry eye	2/63 (3.2%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		0/40 (0%)
Eye pain	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Lacrimation increased	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Vision blurred	6/63 (9.5%)		2/59 (3.4%)		2/20 (10%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Visual impairment	1/63 (1.6%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Gastrointestinal disorders
Abdominal discomfort	2/63 (3.2%)		3/59 (5.1%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Abdominal distension	1/63 (1.6%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		4/40 (10%)
Abdominal pain	11/63 (17.5%)		11/59 (18.6%)		2/20 (10%)		0/9 (0%)		4/40 (10%)		3/40 (7.5%)
Abdominal pain lower	2/63 (3.2%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Abdominal pain upper	1/63 (1.6%)		4/59 (6.8%)		2/20 (10%)		0/9 (0%)		5/40 (12.5%)		4/40 (10%)
Constipation	18/63 (28.6%)		14/59 (23.7%)		5/20 (25%)		0/9 (0%)		14/40 (35%)		8/40 (20%)
Diarrhoea	28/63 (44.4%)		25/59 (42.4%)		5/20 (25%)		3/9 (33.3%)		13/40 (32.5%)		14/40 (35%)
Dry mouth	5/63 (7.9%)		5/59 (8.5%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Dyspepsia	4/63 (6.3%)		8/59 (13.6%)		3/20 (15%)		0/9 (0%)		5/40 (12.5%)		3/40 (7.5%)
Dysphagia	1/63 (1.6%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Gastritis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Gastrointestinal pain	1/63 (1.6%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Gastrooesophageal reflux disease	4/63 (6.3%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Haemorrhoids	2/63 (3.2%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nausea	20/63 (31.7%)		25/59 (42.4%)		11/20 (55%)		0/9 (0%)		11/40 (27.5%)		14/40 (35%)
Toothache	0/63 (0%)		2/59 (3.4%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Vomiting	11/63 (17.5%)		13/59 (22%)		3/20 (15%)		0/9 (0%)		8/40 (20%)		5/40 (12.5%)
General disorders
Asthenia	11/63 (17.5%)		16/59 (27.1%)		0/20 (0%)		1/9 (11.1%)		3/40 (7.5%)		8/40 (20%)
Chest pain	4/63 (6.3%)		6/59 (10.2%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Chills	5/63 (7.9%)		4/59 (6.8%)		3/20 (15%)		0/9 (0%)		8/40 (20%)		5/40 (12.5%)
Fatigue	32/63 (50.8%)		34/59 (57.6%)		13/20 (65%)		5/9 (55.6%)		18/40 (45%)		9/40 (22.5%)
Feeling hot	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Gait disturbance	1/63 (1.6%)		3/59 (5.1%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		2/40 (5%)
Influenza like illness	0/63 (0%)		8/59 (13.6%)		0/20 (0%)		1/9 (11.1%)		1/40 (2.5%)		0/40 (0%)
Malaise	1/63 (1.6%)		2/59 (3.4%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Nodule	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Oedema peripheral	6/63 (9.5%)		8/59 (13.6%)		3/20 (15%)		0/9 (0%)		2/40 (5%)		3/40 (7.5%)
Pain	5/63 (7.9%)		1/59 (1.7%)		3/20 (15%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Peripheral swelling	1/63 (1.6%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Pyrexia	15/63 (23.8%)		9/59 (15.3%)		5/20 (25%)		2/9 (22.2%)		5/40 (12.5%)		3/40 (7.5%)
Unevaluable event	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Immune system disorders
Hypogammaglobulinaemia	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		1/40 (2.5%)		0/40 (0%)
Seasonal allergy	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Infections and infestations
Candida infection	2/63 (3.2%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		2/40 (5%)
Ear infection	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Gastroenteritis viral	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Herpes zoster	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		2/40 (5%)
Infection	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Influenza	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Mucosal infection	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Oesophageal candidiasis	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Oral candidiasis	2/63 (3.2%)		2/59 (3.4%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Oropharyngeal candidiasis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Otitis externa	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pharyngitis	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pilonidal cyst	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rash pustular	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rhinitis	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Sinusitis	0/63 (0%)		1/59 (1.7%)		2/20 (10%)		2/9 (22.2%)		2/40 (5%)		0/40 (0%)
Tooth infection	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Upper respiratory tract infection	5/63 (7.9%)		2/59 (3.4%)		3/20 (15%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Urinary tract infection	6/63 (9.5%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		1/40 (2.5%)
Nasopharyngitis	2/63 (3.2%)		1/59 (1.7%)		4/20 (20%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Injury, poisoning and procedural complications
Animal bite	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Contusion	1/63 (1.6%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Fall	1/63 (1.6%)		2/59 (3.4%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		2/40 (5%)
Infusion related reaction	3/63 (4.8%)		1/59 (1.7%)		2/20 (10%)		1/9 (11.1%)		7/40 (17.5%)		3/40 (7.5%)
Procedural pain	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Radiation skin injury	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Skin Abrasion	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		1/9 (11.1%)		1/40 (2.5%)		0/40 (0%)
Investigations
Alanine aminotransferase increased	2/63 (3.2%)		2/59 (3.4%)		0/20 (0%)		1/9 (11.1%)		3/40 (7.5%)		1/40 (2.5%)
Aspartate aminotransferase increased	2/63 (3.2%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		4/40 (10%)		2/40 (5%)
Blood creatinine increased	2/63 (3.2%)		1/59 (1.7%)		0/20 (0%)		1/9 (11.1%)		1/40 (2.5%)		1/40 (2.5%)
Blood potassium decreased	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Lipase increased	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Neutrophil count decreased	0/63 (0%)		4/59 (6.8%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Platelet count decreased	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		2/40 (5%)
Protein total decreased	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Weight decreased	6/63 (9.5%)		7/59 (11.9%)		3/20 (15%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Weight increased	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
White blood cell count decreased	1/63 (1.6%)		4/59 (6.8%)		0/20 (0%)		1/9 (11.1%)		2/40 (5%)		1/40 (2.5%)
Metabolism and nutrition disorders
Decreased appetite	13/63 (20.6%)		17/59 (28.8%)		4/20 (20%)		0/9 (0%)		7/40 (17.5%)		5/40 (12.5%)
Dehydration	6/63 (9.5%)		3/59 (5.1%)		2/20 (10%)		0/9 (0%)		4/40 (10%)		2/40 (5%)
Gout	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hypercalcaemia	1/63 (1.6%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		2/40 (5%)
Hyperglycaemia	8/63 (12.7%)		4/59 (6.8%)		2/20 (10%)		1/9 (11.1%)		1/40 (2.5%)		4/40 (10%)
Hyperuricaemia	2/63 (3.2%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		1/40 (2.5%)
Hypokalaemia	7/63 (11.1%)		8/59 (13.6%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		5/40 (12.5%)
Hypomagnesaemia	5/63 (7.9%)		6/59 (10.2%)		1/20 (5%)		1/9 (11.1%)		1/40 (2.5%)		2/40 (5%)
Hyponatraemia	1/63 (1.6%)		2/59 (3.4%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hypophosphataemia	2/63 (3.2%)		3/59 (5.1%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Type 2 diabetes mellitus	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia	9/63 (14.3%)		11/59 (18.6%)		5/20 (25%)		1/9 (11.1%)		4/40 (10%)		3/40 (7.5%)
Arthritis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Back pain	7/63 (11.1%)		8/59 (13.6%)		3/20 (15%)		0/9 (0%)		2/40 (5%)		5/40 (12.5%)
Bone pain	1/63 (1.6%)		6/59 (10.2%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Groin pain	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Joint stiffness	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Muscle spasms	5/63 (7.9%)		6/59 (10.2%)		2/20 (10%)		0/9 (0%)		3/40 (7.5%)		0/40 (0%)
Muscle tightness	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Muscular weakness	2/63 (3.2%)		6/59 (10.2%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Musculoskeletal chest pain	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Musculoskeletal discomfort	0/63 (0%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Musculoskeletal pain	4/63 (6.3%)		5/59 (8.5%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Myalgia	7/63 (11.1%)		6/59 (10.2%)		3/20 (15%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Osteopenia	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pain in extremity	7/63 (11.1%)		12/59 (20.3%)		4/20 (20%)		1/9 (11.1%)		7/40 (17.5%)		6/40 (15%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of skin	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Squamous cell carcinoma	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nervous system disorders
Carpal tunnel syndrome	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Cluster headache	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Cognitive disorder	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Cubital tunnel syndrome	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Dizziness	7/63 (11.1%)		10/59 (16.9%)		3/20 (15%)		0/9 (0%)		6/40 (15%)		4/40 (10%)
Dysgeusia	2/63 (3.2%)		3/59 (5.1%)		1/20 (5%)		0/9 (0%)		3/40 (7.5%)		0/40 (0%)
Headache	10/63 (15.9%)		8/59 (13.6%)		6/20 (30%)		1/9 (11.1%)		10/40 (25%)		6/40 (15%)
Hypoaesthesia	3/63 (4.8%)		2/59 (3.4%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Memory impairment	1/63 (1.6%)		3/59 (5.1%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nerve compression	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Neuropathy peripheral	23/63 (36.5%)		27/59 (45.8%)		6/20 (30%)		1/9 (11.1%)		8/40 (20%)		8/40 (20%)
Paraesthesia	5/63 (7.9%)		1/59 (1.7%)		2/20 (10%)		0/9 (0%)		4/40 (10%)		3/40 (7.5%)
Peripheral motor neuropathy	2/63 (3.2%)		5/59 (8.5%)		1/20 (5%)		0/9 (0%)		4/40 (10%)		0/40 (0%)
Peripheral sensory neuropathy	16/63 (25.4%)		17/59 (28.8%)		11/20 (55%)		2/9 (22.2%)		7/40 (17.5%)		2/40 (5%)
Restless legs syndrome	3/63 (4.8%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		1/40 (2.5%)
Syncope	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Tremor	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Hepatic Encephalopathy	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Taste Disorder	0/63 (0%)		3/59 (5.1%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Psychiatric disorders
Adjustment disorder with depressed mood	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Anxiety	2/63 (3.2%)		5/59 (8.5%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Depression	3/63 (4.8%)		4/59 (6.8%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Hallucination olfactory	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Insomnia	15/63 (23.8%)		8/59 (13.6%)		3/20 (15%)		1/9 (11.1%)		1/40 (2.5%)		6/40 (15%)
Renal and urinary disorders
Dysuria	1/63 (1.6%)		3/59 (5.1%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Nocturia	0/63 (0%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		0/40 (0%)
Urinary hesitation	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	9/63 (14.3%)		15/59 (25.4%)		3/20 (15%)		1/9 (11.1%)		7/40 (17.5%)		6/40 (15%)
Dysphonia	1/63 (1.6%)		2/59 (3.4%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		2/40 (5%)
Dyspnoea	11/63 (17.5%)		11/59 (18.6%)		2/20 (10%)		0/9 (0%)		5/40 (12.5%)		8/40 (20%)
Dyspnoea exertional	1/63 (1.6%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Epistaxis	3/63 (4.8%)		1/59 (1.7%)		2/20 (10%)		0/9 (0%)		1/40 (2.5%)		2/40 (5%)
Hiccups	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hypoxia	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		2/40 (5%)		2/40 (5%)
Nasal congestion	4/63 (6.3%)		2/59 (3.4%)		2/20 (10%)		1/9 (11.1%)		4/40 (10%)		3/40 (7.5%)
Oropharyngeal pain	6/63 (9.5%)		0/59 (0%)		3/20 (15%)		1/9 (11.1%)		2/40 (5%)		3/40 (7.5%)
Orthopnoea	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Pleural effusion	2/63 (3.2%)		0/59 (0%)		2/20 (10%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Productive cough	1/63 (1.6%)		3/59 (5.1%)		4/20 (20%)		2/9 (22.2%)		4/40 (10%)		2/40 (5%)
Pulmonary congestion	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rhinitis allergic	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rhinorrhoea	3/63 (4.8%)		0/59 (0%)		2/20 (10%)		2/9 (22.2%)		1/40 (2.5%)		2/40 (5%)
Sinus congestion	1/63 (1.6%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Sneezing	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		1/40 (2.5%)
Bronchiectasis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Skin and subcutaneous tissue disorders
Acne	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Actinic keratosis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Alopecia	10/63 (15.9%)		7/59 (11.9%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		1/40 (2.5%)
Brow ptosis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Dermatitis	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Dermatitis acneiform	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Dry skin	3/63 (4.8%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		3/40 (7.5%)		2/40 (5%)
Erythema	4/63 (6.3%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		3/40 (7.5%)		1/40 (2.5%)
Hyperhidrosis	2/63 (3.2%)		4/59 (6.8%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Night sweats	6/63 (9.5%)		4/59 (6.8%)		3/20 (15%)		0/9 (0%)		6/40 (15%)		1/40 (2.5%)
Pruritus	3/63 (4.8%)		6/59 (10.2%)		2/20 (10%)		0/9 (0%)		7/40 (17.5%)		3/40 (7.5%)
Rash erythematous	0/63 (0%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Rash pruritic	2/63 (3.2%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		1/40 (2.5%)		0/40 (0%)
Rash	3/63 (4.8%)		3/59 (5.1%)		0/20 (0%)		0/9 (0%)		1/40 (2.5%)		1/40 (2.5%)
Surgical and medical procedures
Thrombolysis	0/63 (0%)		0/59 (0%)		0/20 (0%)		1/9 (11.1%)		0/40 (0%)		0/40 (0%)
Vascular disorders
Flushing	1/63 (1.6%)		0/59 (0%)		0/20 (0%)		0/9 (0%)		4/40 (10%)		1/40 (2.5%)
Haematoma	0/63 (0%)		1/59 (1.7%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		2/40 (5%)
Hypertension	0/63 (0%)		3/59 (5.1%)		0/20 (0%)		0/9 (0%)		0/40 (0%)		0/40 (0%)
Hypotension	4/63 (6.3%)		1/59 (1.7%)		1/20 (5%)		0/9 (0%)		2/40 (5%)		4/40 (10%)
Orthostatic hypotension	0/63 (0%)		0/59 (0%)		1/20 (5%)		0/9 (0%)		0/40 (0%)		0/40 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact

Name/Title	Medical Communications
Organization	Hoffmann-La Roche
Phone	800-821-8590
Email	genentech@druginfo.com

Responsible Party:

Genentech, Inc.

ClinicalTrials.gov Identifier:

NCT01691898

Other Study ID Numbers:

GO27834
2011-004377-84

First Posted:

Sep 25, 2012

Last Update Posted:

Feb 21, 2020

Last Verified:

Feb 1, 2020

ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Study Details

Study Description

Brief Summary

Study Design

Arms and Interventions

Outcome Measures

Primary Outcome Measures

Secondary Outcome Measures

Eligibility Criteria

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Locations

Sponsors and Collaborators

Investigators

Study Documents (Full-Text)

More Information

Publications

Study Results

Participant Flow

Baseline Characteristics

Outcome Measures

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Adverse Events

All Cause Mortality

Serious Adverse Events

Other (Not Including Serious) Adverse Events